



January 21, 2020
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Announcement of Joint Research Agreement for New Antibodies with MabGenesis Inc.

Tokyo, January 21, 2020 – Gene Techno Science Co., Ltd. (“GTS”) executed a joint development agreement with MabGenesis Inc. (“MabGenesis”) to obtain and apply patent for new antibodies with the effect of killing cancer cells.

1. Purpose and background for concluding this agreement

This agreement aims to expand the new pipeline in the new biologic business, which is a future growth driver for our company. Recently, efficiency in cancer treatments has been improved with the emergence of antibody drugs and antibody drug conjugates in addition to conventional small molecule drugs. Furthermore, the realization of antibody drugs with new molecular mechanisms of action, such as Opdivo, has become a long-awaited solution for patients previously considered as untreatable. However, there are still many patients who cannot be cured with those drugs. In fact, R&D for rare and intractable cancers with small number of patients is inactive for financial reasons at present, and therefore development of new cancer treatment is essential.

MabGenesis is a bio venture company aiming to obtain a first-in-class, best-in-class monoclonal antibody using innovative and ingenious antibody isolation technology owned by Professor Kazuhiro Morishita, University of Miyazaki and Lecturer Gene Kurosawa, Fujita Health University. Focusing on this technology, GTS signed a joint research agreement with the aim of executing the development of cancer treatments with a new mechanism of action for rare and intractable cancers by acquiring monoclonal antibodies that bind specifically and firmly to specific antigens expressed on the surface of cancer cells.

2. Contents of this agreement

Joint research agreement for acquisition of monoclonal antibodies to specific antigens expressed on the surface of cancer cells

3. Outline of counterparties to this agreement

1. Company Name	MabGenesis Inc.
2. Name and title of representatives	Chief Executive Officer Katsuhiko Shinjo
3. Head Office	1-4, Honcho, Nihonbashi, Chuo-ku, Tokyo
4. Established	June 3 rd , 2019
5. Main Business	Research and development of pharmaceutical drugs
6. Capital	21,750 thousand Japanese Yen

4. Future outlook

The impact on the business results for the fiscal year ending March 2020 is expected to be minimal.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: info@g-gts.com